TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer	HER2-positive Advanced Breast Cancer	Recruiting	Phase 3	2026-06-03		NCT07047365

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	32

75 results · Page 1 of 3

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
3201 Hospital	Hanzhong	China	2
Affiliated Cancer Hospital of Guangxi Medical Universit	Nanning	China	1
Affiliated Hospital of North Sichuan Medical College	Nanchong	China	13
Affiliated Zhongshan Hospital of Dalian University	Dalian	China	14
Anhui Provincial Hospital( The First Affiliated Hospital of USTC)	Hefei	China	1
Anyang Tumor Hospital	Anyang	China	10
Bao Ji Central Hospital	Baoji	China	1
Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)	Jinan	China	3
Chong Qing University Cancer Hospital	Chongqing	China	1
Fuzhou First Generel Hospital Affiliated with Fujian Medical University	Fuzhou	China	1
Gansu Cancer Hospital	Lanzhou	China	6
Ganzhou Cancer Hospital	Ganzhou	China	3
Ganzhou People's Hospital	Ganzhou	China	4
Guizhou Provincial People's Hospital	Guiyang	China	24
Hainan General Hospital	Haikou	China	21
Harbin Medical University Cancer Hospital	Harbin	China	45
Henan Cancer Hospital	Zhengzhou	China	76
Hunan Cancer Hospital	Changsha	China	41
Jiamusi Tuberculosis Hospital (Jiamusi Tumor Hospital)	Jiamusi	China	2
JiangSu Cancer Hosipital	Nanjing	China	1
Jiangxi Cancer Hospital	Nanchang	China	48
Jilin Cancer Hospital	Changchun	China	27
Jingmen people's hospital	Jingmen	China	3
Liaoning Cancer Hospital & Institute	Shenyang	China	1
LinYi Cancer Hospital	Linyi	China	11

Clinical trials